Drugs · acquisition-cost intelligence
Memantine Hydrochloride
memantine· ingredient memantineOther anti-dementia drugs· MEMANTINE HYDROCHLORIDE 14 mg/1; MEMANTINE HYDROCHLORIDE 21 mg/1; MEMANTINE HYDROCHLORIDE 28 mg/1; MEMANTINE HYDROCHLORIDE 7 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.32570
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other memantine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| memantine hydrochloride | $0.06562 | −$0.26010 |
| MEMANTINE | $0.60879 | +$0.28310 |
Medicare Part D coverage · CY2026
On 289 plan formularies · typical tier 4
Prior auth 50% · Step therapy 19% · Quantity limit 51% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.